--- title: "Indivior Posts Strong Q1 Results, Raises 2026 Outlook" type: "News" locale: "en" url: "https://longbridge.com/en/news/284762877.md" description: "Indivior reported strong Q1 2026 results with a 19% year-on-year revenue increase to $317 million, driven by a 32% rise in SUBLOCADE revenue. The company raised its full-year guidance, projecting total net revenue of $1.215 billion–$1.285 billion. Indivior also improved profitability with record adjusted EBITDA of $164 million and nearly doubled GAAP net income to $89 million. Additionally, it executed a $500 million convertible notes issue and $125 million in share repurchases. Analyst ratings for INDV stock are mixed, with a Buy rating and a price target of $54.00, while Spark rates it as Neutral due to financial quality concerns." datetime: "2026-04-30T11:51:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284762877.md) - [en](https://longbridge.com/en/news/284762877.md) - [zh-HK](https://longbridge.com/zh-HK/news/284762877.md) generator: "portal-rs" --- # Indivior Posts Strong Q1 Results, Raises 2026 Outlook ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Indivior ( (INDV) ) has issued an announcement. Indivior reported strong first-quarter 2026 results on April 30, 2026, with total net revenue rising 19% year-on-year to $317 million and SUBLOCADE net revenue up 32% to $232 million, driven by 20% U.S. volume growth and record new patient starts. The company delivered record adjusted EBITDA of $164 million, sharply reduced operating expenses, and GAAP net income nearly doubled to $89 million, underscoring improved profitability. On the back of this performance, Indivior raised its full-year 2026 guidance, lifting total net revenue expectations to $1.215 billion–$1.285 billion and SUBLOCADE revenue to $950 million–$990 million, while projecting significantly higher adjusted EBITDA. The group also strengthened its balance sheet with a $500 million convertible notes issue used largely to repay term debt, executed $125 million of share repurchases under a $400 million program, and reoriented its pipeline by handing back INDV-6001 development to Alar and halting internal development of INDV-2000 after a Phase 2 miss, while seeking external opportunities for the asset. The most recent analyst rating on (INDV) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page. **Spark’s Take on INDV Stock** According to Spark, TipRanks’ AI Analyst, INDV is a Neutral. The score is held back primarily by weaker financial quality (negative equity and inconsistent/negative cash flow despite improved profitability) and bearish technicals. Offsetting these, the latest earnings call guidance points to strong 2026 EBITDA and operating cash flow improvement, while valuation appears mid-range with no dividend support. To see Spark’s full report on INDV stock, click here. **More about Indivior** Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treatments for opioid use disorder, where it is a leader in long-acting injectable therapies. Its primary product is SUBLOCADE, a monthly injectable buprenorphine formulation, with a core market focus on the U.S. addiction treatment landscape and related healthcare settings. **Average Trading Volume:** 2,368,335 **Technical Sentiment Signal:** Buy **Current Market Cap:** $4.16B For a thorough assessment of INDV stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [INDV.US](https://longbridge.com/en/quote/INDV.US.md) - [INDV.UK](https://longbridge.com/en/quote/INDV.UK.md) ## Related News & Research - [Indivior Q2 2026 Earnings Call: Complete Transcript](https://longbridge.com/en/news/296085674.md) - [Indivior Q2 FY26 GAAP net income rises to $122 million; revenue increases 14% to $343 million YoY](https://longbridge.com/en/news/294679226.md) - [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md) - [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md) - [Indivior Chief Accounting Officer Woodrow D Anderson acquires 1,500 shares worth $54,420](https://longbridge.com/en/news/295014018.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**